Navigation Links
Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Date:11/15/2010

harmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. Results were presented by the company's Chief Scientific Officer, Dr. Miriam Kidron, at the Tenth Annual Meeting of the Diabetes Technology Society, in Bethesda, Maryland.

The poster presentation entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," described Oramed's first extended exposure study to its oral insulin product (ORMD-0801), where 21 patients were treated with ORMD-0801, self-administered daily for a period of six weeks. In parallel, a group of eight patients received placebo capsules administered under the same treatment regimen. ORMD-0801 proved safe and tolerable, with no reports of serious adverse events throughout the study. In addition, no cumulative effects of extended ORMD-0801 exposure were noted, and only two mild cases of transient hypoglycemia were reported. Treatment efficacy was evaluated via markers quantified from blood samples drawn at the start and end of the study. Daily administration of oral insulin led to a statistically significant decrease in both insulin and C-reactive protein (CRP) levels, in contrast to their elevation among placebo-treated individuals. Moreover, the percentage of subjects demonstrating clinically relevant reductions in insulin, c-peptide, fasting blood glucose (FBG) and Hb1Ac levels was consistently higher in the ORMD-0801 cohort, when compared to its placebo counterpart. This study addressing, for the first time, potential long-term safety concerns from extended ORMD-0801 administrations, demonstrated safety and no seri
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
2. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
8. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
9. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
10. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea Corporate ... development in Downtown Toronto is expanding at a blistering ... storeys of new development last week (including three new ... the Toronto skyline for the foreseeable future in a ... new development. , As the Toronto city council met ...
(Date:9/15/2014)... UPTON, NYHeat drives classical phase transitionsthink solid, ... happen when the temperature drops. If phase ... where quantum mechanics reigns, subtle fluctuations can ... from the U.S. Department of Energy,s Brookhaven ... explored this frigid landscape of absolute zero ...
(Date:9/15/2014)... United States (PRWEB) September 16, 2014 ... Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies is ... This report focuses on the three principal types ... of research and development in cancer immunotherapy (which ... inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... SAN JOSE, Calif. , Sept. 15, 2014 ... for Proposals (RFP) for flexible, printed product demonstrators ... conducts a two-stage RFP process with pre-proposals due ... in January 2015.  Funds for proposals ultimately selected ... (ARL) and have a significant cost share by ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... (OTC Bulletin Board: MNCN), an innovative, global wellness solutions company, ... the OTC Bulletin Board under the symbol "MNCN." The Company,s ... , "The move to the OTC Bulletin Board will ... investors and help improve our trading liquidity," said Patrick Sheridan, ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... announced today that it has received a European ... technology for the improved oral delivery of drugs. ... Reverse Micelle Compositions and Uses Thereof" covers lipid ...
... July 8 iZumi Bio, Inc. and Pierian, Inc. ... company, iPierian, Inc. Building on the iZumi infrastructure and ... cellular reprogramming to change the paradigm of drug discovery. ... development of new therapeutics using induced pluripotent stem (iPS) ...
Cached Biology Technology:DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 2DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 3DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 4DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 2iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 3iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 4iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 6
(Date:9/16/2014)... XL pipeline (KXL) would likely increase oil sands extraction, ... by the non-profit organization Near Zero. The results are ... and includes both supporters and opponents of the pipeline. ... could lead to significantly higher greenhouse gas emissions, with ... , "This report examines three main scenarios discussed ...
(Date:9/16/2014)... DURHAM, N.H. From the salmon-rich waters of Southeast ... Coast to Downeast Maine,s lobster, lumber and tourist towns, ... their views about coastal environments divide along political lines. ... University of New Hampshire sociologists published this month in ... "We found a lot of environment-related differences from place ...
(Date:9/16/2014)... 2014  Valencell, Inc., a leader in performance biometric ... 18 "Showcase Companies" representing North Carolina,s ... Tech Venture Conference on September 16-17 th at ... Raleigh, North Carolina . Valencell,s President ... during the "Digital Health Spotlight Sector" on how the ...
Breaking Biology News(10 mins):Keystone XL would likely raise oil sands production and greenhouse gas emissions 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... researchers will embark on an unconventional approach to DNA research ... for the ideas to explore scientific frontiers. Chemist Patrick ... were the youngest researchers chosen among several hundred applicants. They ... a senior scientist, growth biology Prof. Rod Hill. The ...
... A long-term field and DNA study by the ... University of Miami, Field Museum of Chicago and others ... Bimini islands, Bahamas, tend to stay near their coastal ... typically focuses on baby sharks confined to shallow habitats, ...
... produced more cheaply using nanoparticle "inks" that allow them ... sides of buildings or rooftops to absorb electricity-producing sunlight. ... chemical engineer, is hoping to cut costs to one-tenth ... process for solar cells gas-phase deposition in a ...
Cached Biology News:Idaho researchers win grant to explore DNA frontier 2Scientists shed new light on behavior of shark 'tweens' and 'teenagers' 2Scientists shed new light on behavior of shark 'tweens' and 'teenagers' 3Lower-cost solar cells to be printed like newspaper, painted on rooftops 2
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Biology Products: